Advertisement

Index by author

December 01, 1996; Volume 50,Issue 6

A

  1. Aiyar, J

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  2. Andrews, A M

    1. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals.
      A M Andrews, B Ladenheim, C J Epstein, J L Cadet and D L Murphy
      Molecular Pharmacology December 1996, 50 (6) 1511-1519;

  3. Austin, C A

    1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
      M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
      Molecular Pharmacology December 1996, 50 (6) 1463-1471;

B

  1. Barbhaiya, H

    1. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding.
      H Barbhaiya, R McClain, A Ijzerman and S A Rivkees
      Molecular Pharmacology December 1996, 50 (6) 1635-1642;

  2. Biggers, M S

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  3. Bray, P G

    1. 4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake.
      P G Bray, S R Hawley and S A Ward
      Molecular Pharmacology December 1996, 50 (6) 1551-1558;
    2. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum.
      P G Bray, S R Hawley, M Mungthin and S A Ward
      Molecular Pharmacology December 1996, 50 (6) 1559-1566;

  4. Brown, R

    1. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
      P A Vasey, N A Jones, S Jenkins, C Dive and R Brown
      Molecular Pharmacology December 1996, 50 (6) 1536-1540;

  5. Bruns, M J

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

C

  1. Cadet, J L

    1. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals.
      A M Andrews, B Ladenheim, C J Epstein, J L Cadet and D L Murphy
      Molecular Pharmacology December 1996, 50 (6) 1511-1519;

  2. Cahalan, M D

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  3. Calderon, S N

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  4. Canniff, P C

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  5. Capranico, G

    1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
      M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
      Molecular Pharmacology December 1996, 50 (6) 1463-1471;

  6. Cascieri, M A

    1. Relative contribution of polar interactions and conformational compatibility to the binding of neurokinin-1 receptor antagonists.
      T M Fong, H Yu, R R Huang, M A Cascieri and C J Swain
      Molecular Pharmacology December 1996, 50 (6) 1605-1611;

  7. Cass, C E

    1. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes.
      S Y Yao, A M Ng, M W Ritzel, W P Gati, C E Cass and J D Young
      Molecular Pharmacology December 1996, 50 (6) 1529-1535;

  8. Chandy, K G

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  9. Chen, L

    1. Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs.
      Y Xu, B A Gilbert, R R Rando, L Chen and A H Tashjian
      Molecular Pharmacology December 1996, 50 (6) 1495-1501;

  10. Chen, M S

    1. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells.
      T Cihlar and M S Chen
      Molecular Pharmacology December 1996, 50 (6) 1502-1510;

  11. Chignell, C F

    1. Acid-catalyzed oxidation of the anticancer agent mitoxantrone by nitrite ions.
      K J Reszka and C F Chignell
      Molecular Pharmacology December 1996, 50 (6) 1612-1618;

  12. Chiu, T T

    1. Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation.
      T T Chiu, L Y Yung and Y H Wong
      Molecular Pharmacology December 1996, 50 (6) 1651-1657;

  13. Cihlar, T

    1. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells.
      T Cihlar and M S Chen
      Molecular Pharmacology December 1996, 50 (6) 1502-1510;

  14. Cornarotti, M

    1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
      M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
      Molecular Pharmacology December 1996, 50 (6) 1463-1471;

  15. Covey, D F

    1. Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
      L L Wittmer, Y Hu, M Kalkbrenner, A S Evers, C F Zorumski and D F Covey
      Molecular Pharmacology December 1996, 50 (6) 1581-1586;

  16. Curtis, N R

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

D

  1. De Neef, P

    1. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
      J Van Rampelbergh, P Gourlet, P De Neef, P Robberecht and M Waelbroeck
      Molecular Pharmacology December 1996, 50 (6) 1596-1604;

  2. Dive, C

    1. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
      P A Vasey, N A Jones, S Jenkins, C Dive and R Brown
      Molecular Pharmacology December 1996, 50 (6) 1536-1540;

  3. Donovan, C B

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

E

  1. Emms, F

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

  2. Epstein, C J

    1. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals.
      A M Andrews, B Ladenheim, C J Epstein, J L Cadet and D L Murphy
      Molecular Pharmacology December 1996, 50 (6) 1511-1519;

  3. Evers, A S

    1. Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
      L L Wittmer, Y Hu, M Kalkbrenner, A S Evers, C F Zorumski and D F Covey
      Molecular Pharmacology December 1996, 50 (6) 1581-1586;

F

  1. Figler, R A

    1. Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
      R A Figler, S G Graber, M A Lindorfer, H Yasuda, J Linden and J C Garrison
      Molecular Pharmacology December 1996, 50 (6) 1587-1595;

  2. Fisher, L M

    1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
      M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
      Molecular Pharmacology December 1996, 50 (6) 1463-1471;

  3. Fong, T M

    1. Relative contribution of polar interactions and conformational compatibility to the binding of neurokinin-1 receptor antagonists.
      T M Fong, H Yu, R R Huang, M A Cascieri and C J Swain
      Molecular Pharmacology December 1996, 50 (6) 1605-1611;

  4. Freedman, S B

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

  5. Freissmuth, M

    1. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
      M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
      Molecular Pharmacology December 1996, 50 (6) 1443-1453;

  6. Fujimori, A

    1. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
      A Fujimori, M Gupta, Y Hoki and Y Pommier
      Molecular Pharmacology December 1996, 50 (6) 1472-1478;

G

  1. Garrison, J C

    1. Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
      R A Figler, S G Graber, M A Lindorfer, H Yasuda, J Linden and J C Garrison
      Molecular Pharmacology December 1996, 50 (6) 1587-1595;

  2. Gati, W P

    1. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes.
      S Y Yao, A M Ng, M W Ritzel, W P Gati, C E Cass and J D Young
      Molecular Pharmacology December 1996, 50 (6) 1529-1535;

  3. Gilbert, B A

    1. Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs.
      Y Xu, B A Gilbert, R R Rando, L Chen and A H Tashjian
      Molecular Pharmacology December 1996, 50 (6) 1495-1501;

  4. Glick, D

    1. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
      Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut and H Soreq
      Molecular Pharmacology December 1996, 50 (6) 1423-1431;

  5. Gluzman, N

    1. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
      Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut and H Soreq
      Molecular Pharmacology December 1996, 50 (6) 1423-1431;

  6. Gommeren, W

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  7. Gourlet, P

    1. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
      J Van Rampelbergh, P Gourlet, P De Neef, P Robberecht and M Waelbroeck
      Molecular Pharmacology December 1996, 50 (6) 1596-1604;

  8. Graber, S G

    1. Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
      R A Figler, S G Graber, M A Lindorfer, H Yasuda, J Linden and J C Garrison
      Molecular Pharmacology December 1996, 50 (6) 1587-1595;

  9. Grant, A O

    1. The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels.
      A O Grant, J E John, V V Nesterenko, C F Starmer and J R Moorman
      Molecular Pharmacology December 1996, 50 (6) 1643-1650;

  10. Grissmer, S

    1. Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3.
      H Rauer and S Grissmer
      Molecular Pharmacology December 1996, 50 (6) 1625-1634;
    2. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  11. Guastella, J

    1. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
      V I Ilyin, E R Whittemore, J Guastella, E Weber and R M Woodward
      Molecular Pharmacology December 1996, 50 (6) 1541-1550;

  12. Gupta, M

    1. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
      A Fujimori, M Gupta, Y Hoki and Y Pommier
      Molecular Pharmacology December 1996, 50 (6) 1472-1478;

  13. Gutman, G A

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

H

  1. Haegeman, G

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  2. Hankinson, O

    1. Basis for the loss of aryl hydrocarbon receptor gene expression in clones of a mouse hepatoma cell line.
      J Zhang, A J Watson, M R Probst, E Minehart and O Hankinson
      Molecular Pharmacology December 1996, 50 (6) 1454-1462;

  3. Hanson, D C

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  4. Hawley, S R

    1. 4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake.
      P G Bray, S R Hawley and S A Ward
      Molecular Pharmacology December 1996, 50 (6) 1551-1558;
    2. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum.
      P G Bray, S R Hawley, M Mungthin and S A Ward
      Molecular Pharmacology December 1996, 50 (6) 1559-1566;

  5. Heinemann, S F

    1. Calcium-dependent inactivation of recombinant N-methyl-D-aspartate receptors is NR2 subunit specific.
      J J Krupp, B Vissel, S F Heinemann and G L Westbrook
      Molecular Pharmacology December 1996, 50 (6) 1680-1688;

  6. Herrmann-Frank, A

    1. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
      M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
      Molecular Pharmacology December 1996, 50 (6) 1443-1453;

  7. Heylen, L

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  8. Hohenegger, M

    1. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
      M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
      Molecular Pharmacology December 1996, 50 (6) 1443-1453;

  9. Hoki, Y

    1. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
      A Fujimori, M Gupta, Y Hoki and Y Pommier
      Molecular Pharmacology December 1996, 50 (6) 1472-1478;

  10. Hruby, V J

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  11. Hu, Y

    1. Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
      L L Wittmer, Y Hu, M Kalkbrenner, A S Evers, C F Zorumski and D F Covey
      Molecular Pharmacology December 1996, 50 (6) 1581-1586;

  12. Huang, R R

    1. Relative contribution of polar interactions and conformational compatibility to the binding of neurokinin-1 receptor antagonists.
      T M Fong, H Yu, R R Huang, M A Cascieri and C J Swain
      Molecular Pharmacology December 1996, 50 (6) 1605-1611;

I

  1. Ijzerman, A

    1. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding.
      H Barbhaiya, R McClain, A Ijzerman and S A Rivkees
      Molecular Pharmacology December 1996, 50 (6) 1635-1642;

  2. Ilyin, V I

    1. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
      V I Ilyin, E R Whittemore, J Guastella, E Weber and R M Woodward
      Molecular Pharmacology December 1996, 50 (6) 1541-1550;

J

  1. Jenkins, S

    1. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
      P A Vasey, N A Jones, S Jenkins, C Dive and R Brown
      Molecular Pharmacology December 1996, 50 (6) 1536-1540;

  2. John, J E

    1. The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels.
      A O Grant, J E John, V V Nesterenko, C F Starmer and J R Moorman
      Molecular Pharmacology December 1996, 50 (6) 1643-1650;

  3. Jones, N A

    1. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
      P A Vasey, N A Jones, S Jenkins, C Dive and R Brown
      Molecular Pharmacology December 1996, 50 (6) 1536-1540;

K

  1. Kalkbrenner, M

    1. Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
      L L Wittmer, Y Hu, M Kalkbrenner, A S Evers, C F Zorumski and D F Covey
      Molecular Pharmacology December 1996, 50 (6) 1581-1586;

  2. Kath, J C

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  3. Kawai, K

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  4. Knapp, R J

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  5. Krupp, J J

    1. Calcium-dependent inactivation of recombinant N-methyl-D-aspartate receptors is NR2 subunit specific.
      J J Krupp, B Vissel, S F Heinemann and G L Westbrook
      Molecular Pharmacology December 1996, 50 (6) 1680-1688;

  6. Kulagowski, J J

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

L

  1. Ladenheim, B

    1. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals.
      A M Andrews, B Ladenheim, C J Epstein, J L Cadet and D L Murphy
      Molecular Pharmacology December 1996, 50 (6) 1511-1519;

  2. Landsman, R S

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  3. Lanier, S M

    1. Analysis of the alpha2C-adrenergic receptor gene promoter and its cell-type-specific activity.
      J S Saulnier-Blache, Q Yang, J D Sherlock and S M Lanier
      Molecular Pharmacology December 1996, 50 (6) 1432-1442;

  4. Leeson, P D

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

  5. Lehmann-Horn, F

    1. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
      M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
      Molecular Pharmacology December 1996, 50 (6) 1443-1453;

  6. Lepple-Wienhues, A

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  7. Lesage, A S

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  8. Leysen, J E

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  9. Li, X

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  10. Linden, J

    1. Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
      R A Figler, S G Graber, M A Lindorfer, H Yasuda, J Linden and J C Garrison
      Molecular Pharmacology December 1996, 50 (6) 1587-1595;

  11. Lindorfer, M A

    1. Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
      R A Figler, S G Graber, M A Lindorfer, H Yasuda, J Linden and J C Garrison
      Molecular Pharmacology December 1996, 50 (6) 1587-1595;

  12. Loewenstein-Lichtenstein, Y

    1. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
      Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut and H Soreq
      Molecular Pharmacology December 1996, 50 (6) 1423-1431;

  13. Luyten, W H

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

M

  1. MacEwan, D J

    1. Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells.
      D J MacEwan and G Milligan
      Molecular Pharmacology December 1996, 50 (6) 1479-1486;

  2. Magyar, J

    1. Effects of volatile anesthetics on the G protein-regulated muscarinic potassium channel.
      J Magyar and G Szabo
      Molecular Pharmacology December 1996, 50 (6) 1520-1528;

  3. Malatynska, E

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  4. Marston, D

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

  5. Marwood, R

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

  6. Mather, R J

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  7. Matyash, M

    1. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
      M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
      Molecular Pharmacology December 1996, 50 (6) 1443-1453;

  8. McClain, R

    1. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding.
      H Barbhaiya, R McClain, A Ijzerman and S A Rivkees
      Molecular Pharmacology December 1996, 50 (6) 1635-1642;

  9. Meunier, L

    1. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
      A J Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and A C Roche
      Molecular Pharmacology December 1996, 50 (6) 1487-1494;

  10. Midoux, P

    1. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
      A J Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and A C Roche
      Molecular Pharmacology December 1996, 50 (6) 1487-1494;

  11. Milligan, G

    1. Inverse agonist-induced up-regulation of the human beta2-adrenoceptor in transfected neuroblastoma X glioma hybrid cells.
      D J MacEwan and G Milligan
      Molecular Pharmacology December 1996, 50 (6) 1479-1486;

  12. Minehart, E

    1. Basis for the loss of aryl hydrocarbon receptor gene expression in clones of a mouse hepatoma cell line.
      J Zhang, A J Watson, M R Probst, E Minehart and O Hankinson
      Molecular Pharmacology December 1996, 50 (6) 1454-1462;

  13. Mizusura, A

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  14. Monsigny, M

    1. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
      A J Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and A C Roche
      Molecular Pharmacology December 1996, 50 (6) 1487-1494;

  15. Moorman, J R

    1. The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels.
      A O Grant, J E John, V V Nesterenko, C F Starmer and J R Moorman
      Molecular Pharmacology December 1996, 50 (6) 1643-1650;

  16. Mungthin, M

    1. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum.
      P G Bray, S R Hawley, M Mungthin and S A Ward
      Molecular Pharmacology December 1996, 50 (6) 1559-1566;

  17. Murphy, D L

    1. Transgenic mice with high levels of superoxide dismutase activity are protected from the neurotoxic effects of 2'-NH2-MPTP on serotonergic and noradrenergic nerve terminals.
      A M Andrews, B Ladenheim, C J Epstein, J L Cadet and D L Murphy
      Molecular Pharmacology December 1996, 50 (6) 1511-1519;

N

  1. Nagase, H

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  2. Nesterenko, V V

    1. The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels.
      A O Grant, J E John, V V Nesterenko, C F Starmer and J R Moorman
      Molecular Pharmacology December 1996, 50 (6) 1643-1650;

  3. Ng, A M

    1. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes.
      S Y Yao, A M Ng, M W Ritzel, W P Gati, C E Cass and J D Young
      Molecular Pharmacology December 1996, 50 (6) 1529-1535;

  4. Nguyen, A

    1. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

P

  1. Patel, S

    1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;
    2. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
      S Patel, S Patel, R Marwood, F Emms, D Marston, P D Leeson, N R Curtis, J J Kulagowski and S B Freedman
      Molecular Pharmacology December 1996, 50 (6) 1658-1664;

  2. Pichon, C

    1. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
      A J Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and A C Roche
      Molecular Pharmacology December 1996, 50 (6) 1487-1494;

  3. Pommier, Y

    1. Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
      A Fujimori, M Gupta, Y Hoki and Y Pommier
      Molecular Pharmacology December 1996, 50 (6) 1472-1478;

  4. Poussu, K

    1. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
      M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
      Molecular Pharmacology December 1996, 50 (6) 1443-1453;

  5. Price, C J

    1. Evans blue antagonizes both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate receptors and modulates receptor desensitization.
      C J Price and L A Raymond
      Molecular Pharmacology December 1996, 50 (6) 1665-1671;

  6. Probst, M R

    1. Basis for the loss of aryl hydrocarbon receptor gene expression in clones of a mouse hepatoma cell line.
      J Zhang, A J Watson, M R Probst, E Minehart and O Hankinson
      Molecular Pharmacology December 1996, 50 (6) 1454-1462;

R

  1. Rando, R R

    1. Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs.
      Y Xu, B A Gilbert, R R Rando, L Chen and A H Tashjian
      Molecular Pharmacology December 1996, 50 (6) 1495-1501;

  2. Rauer, H

    1. Evidence for an internal phenylalkylamine action on the voltage-gated potassium channel Kv1.3.
      H Rauer and S Grissmer
      Molecular Pharmacology December 1996, 50 (6) 1625-1634;
    2. Novel nonpeptide agents potently block the C-type inactivated conformation of Kv1.3 and suppress T cell activation.
      A Nguyen, J C Kath, D C Hanson, M S Biggers, P C Canniff, C B Donovan, R J Mather, M J Bruns, H Rauer, J Aiyar, A Lepple-Wienhues, G A Gutman, S Grissmer, M D Cahalan and K G Chandy
      Molecular Pharmacology December 1996, 50 (6) 1672-1679;

  3. Raymond, L A

    1. Evans blue antagonizes both alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate and kainate receptors and modulates receptor desensitization.
      C J Price and L A Raymond
      Molecular Pharmacology December 1996, 50 (6) 1665-1671;

  4. Reszka, K J

    1. Acid-catalyzed oxidation of the anticancer agent mitoxantrone by nitrite ions.
      K J Reszka and C F Chignell
      Molecular Pharmacology December 1996, 50 (6) 1612-1618;

  5. Rice, K

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  6. Ritzel, M W

    1. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes.
      S Y Yao, A M Ng, M W Ritzel, W P Gati, C E Cass and J D Young
      Molecular Pharmacology December 1996, 50 (6) 1529-1535;

  7. Rivkees, S A

    1. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding.
      H Barbhaiya, R McClain, A Ijzerman and S A Rivkees
      Molecular Pharmacology December 1996, 50 (6) 1635-1642;

  8. Robberecht, P

    1. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
      J Van Rampelbergh, P Gourlet, P De Neef, P Robberecht and M Waelbroeck
      Molecular Pharmacology December 1996, 50 (6) 1596-1604;

  9. Roche, A C

    1. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
      A J Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and A C Roche
      Molecular Pharmacology December 1996, 50 (6) 1487-1494;

  10. Roeske, W R

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

S

  1. Sarközi, S

    1. Activation of the skeletal muscle ryanodine receptor by suramin and suramin analogs.
      M Hohenegger, M Matyash, K Poussu, A Herrmann-Frank, S Sarközi, F Lehmann-Horn and M Freissmuth
      Molecular Pharmacology December 1996, 50 (6) 1443-1453;

  2. Saulnier-Blache, J S

    1. Analysis of the alpha2C-adrenergic receptor gene promoter and its cell-type-specific activity.
      J S Saulnier-Blache, Q Yang, J D Sherlock and S M Lanier
      Molecular Pharmacology December 1996, 50 (6) 1432-1442;

  3. Schotte, A

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  4. Sherlock, J D

    1. Analysis of the alpha2C-adrenergic receptor gene promoter and its cell-type-specific activity.
      J S Saulnier-Blache, Q Yang, J D Sherlock and S M Lanier
      Molecular Pharmacology December 1996, 50 (6) 1432-1442;

  5. Soreq, H

    1. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
      Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut and H Soreq
      Molecular Pharmacology December 1996, 50 (6) 1423-1431;

  6. Starmer, C F

    1. The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels.
      A O Grant, J E John, V V Nesterenko, C F Starmer and J R Moorman
      Molecular Pharmacology December 1996, 50 (6) 1643-1650;

  7. Sternfeld, M

    1. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
      Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut and H Soreq
      Molecular Pharmacology December 1996, 50 (6) 1423-1431;

  8. Stewart, A J

    1. Enhanced biological activity of antisense oligonucleotides complexed with glycosylated poly-L-lysine.
      A J Stewart, C Pichon, L Meunier, P Midoux, M Monsigny and A C Roche
      Molecular Pharmacology December 1996, 50 (6) 1487-1494;

  9. Stropova, D

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  10. Swain, C J

    1. Relative contribution of polar interactions and conformational compatibility to the binding of neurokinin-1 receptor antagonists.
      T M Fong, H Yu, R R Huang, M A Cascieri and C J Swain
      Molecular Pharmacology December 1996, 50 (6) 1605-1611;

  11. Szabo, G

    1. Effects of volatile anesthetics on the G protein-regulated muscarinic potassium channel.
      J Magyar and G Szabo
      Molecular Pharmacology December 1996, 50 (6) 1520-1528;

T

  1. Tashjian, A H

    1. Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs.
      Y Xu, B A Gilbert, R R Rando, L Chen and A H Tashjian
      Molecular Pharmacology December 1996, 50 (6) 1495-1501;

  2. Tinelli, S

    1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
      M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
      Molecular Pharmacology December 1996, 50 (6) 1463-1471;

V

  1. Van de Weyer, I

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  2. Van Gompel, P

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  3. Vanhoenacker, P

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

  4. Van Rampelbergh, J

    1. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
      J Van Rampelbergh, P Gourlet, P De Neef, P Robberecht and M Waelbroeck
      Molecular Pharmacology December 1996, 50 (6) 1596-1604;

  5. Varga, E V

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  6. Vasey, P A

    1. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance.
      P A Vasey, N A Jones, S Jenkins, C Dive and R Brown
      Molecular Pharmacology December 1996, 50 (6) 1536-1540;

  7. Vissel, B

    1. Calcium-dependent inactivation of recombinant N-methyl-D-aspartate receptors is NR2 subunit specific.
      J J Krupp, B Vissel, S F Heinemann and G L Westbrook
      Molecular Pharmacology December 1996, 50 (6) 1680-1688;

W

  1. Waelbroeck, M

    1. Properties of the pituitary adenylate cyclase-activating polypeptide I and II receptors, vasoactive intestinal peptide1, and chimeric amino-terminal pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal peptide1 receptors: evidence for multiple receptor states.
      J Van Rampelbergh, P Gourlet, P De Neef, P Robberecht and M Waelbroeck
      Molecular Pharmacology December 1996, 50 (6) 1596-1604;

  2. Ward, S A

    1. 4-Aminoquinoline resistance of Plasmodium falciparum: insights from the study of amodiaquine uptake.
      P G Bray, S R Hawley and S A Ward
      Molecular Pharmacology December 1996, 50 (6) 1551-1558;
    2. Physicochemical properties correlated with drug resistance and the reversal of drug resistance in Plasmodium falciparum.
      P G Bray, S R Hawley, M Mungthin and S A Ward
      Molecular Pharmacology December 1996, 50 (6) 1559-1566;

  3. Watson, A J

    1. Basis for the loss of aryl hydrocarbon receptor gene expression in clones of a mouse hepatoma cell line.
      J Zhang, A J Watson, M R Probst, E Minehart and O Hankinson
      Molecular Pharmacology December 1996, 50 (6) 1454-1462;

  4. Weber, E

    1. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
      V I Ilyin, E R Whittemore, J Guastella, E Weber and R M Woodward
      Molecular Pharmacology December 1996, 50 (6) 1541-1550;

  5. Westbrook, G L

    1. Calcium-dependent inactivation of recombinant N-methyl-D-aspartate receptors is NR2 subunit specific.
      J J Krupp, B Vissel, S F Heinemann and G L Westbrook
      Molecular Pharmacology December 1996, 50 (6) 1680-1688;

  6. Whittemore, E R

    1. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
      V I Ilyin, E R Whittemore, J Guastella, E Weber and R M Woodward
      Molecular Pharmacology December 1996, 50 (6) 1541-1550;

  7. Willmore, E

    1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
      M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
      Molecular Pharmacology December 1996, 50 (6) 1463-1471;

  8. Wittmer, L L

    1. Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
      L L Wittmer, Y Hu, M Kalkbrenner, A S Evers, C F Zorumski and D F Covey
      Molecular Pharmacology December 1996, 50 (6) 1581-1586;

  9. Wong, Y H

    1. Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation.
      T T Chiu, L Y Yung and Y H Wong
      Molecular Pharmacology December 1996, 50 (6) 1651-1657;

  10. Woodward, R M

    1. Subtype-selective inhibition of N-methyl-D-aspartate receptors by haloperidol.
      V I Ilyin, E R Whittemore, J Guastella, E Weber and R M Woodward
      Molecular Pharmacology December 1996, 50 (6) 1541-1550;

  11. Wouters, R

    1. Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamine and [3H]alniditan.
      J E Leysen, W Gommeren, L Heylen, W H Luyten, I Van de Weyer, P Vanhoenacker, G Haegeman, A Schotte, P Van Gompel, R Wouters and A S Lesage
      Molecular Pharmacology December 1996, 50 (6) 1567-1580;

X

  1. Xu, Y

    1. Inhibition of capacitative Ca2+ entry into cells by farnesylcysteine analogs.
      Y Xu, B A Gilbert, R R Rando, L Chen and A H Tashjian
      Molecular Pharmacology December 1996, 50 (6) 1495-1501;

Y

  1. Yamamura, H I

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  2. Yang, Q

    1. Analysis of the alpha2C-adrenergic receptor gene promoter and its cell-type-specific activity.
      J S Saulnier-Blache, Q Yang, J D Sherlock and S M Lanier
      Molecular Pharmacology December 1996, 50 (6) 1432-1442;

  3. Yao, S Y

    1. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes.
      S Y Yao, A M Ng, M W Ritzel, W P Gati, C E Cass and J D Young
      Molecular Pharmacology December 1996, 50 (6) 1529-1535;

  4. Yasuda, H

    1. Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
      R A Figler, S G Graber, M A Lindorfer, H Yasuda, J Linden and J C Garrison
      Molecular Pharmacology December 1996, 50 (6) 1587-1595;

  5. Young, J D

    1. Transport of adenosine by recombinant purine- and pyrimidine-selective sodium/nucleoside cotransporters from rat jejunum expressed in Xenopus laevis oocytes.
      S Y Yao, A M Ng, M W Ritzel, W P Gati, C E Cass and J D Young
      Molecular Pharmacology December 1996, 50 (6) 1529-1535;

  6. Yu, H

    1. Relative contribution of polar interactions and conformational compatibility to the binding of neurokinin-1 receptor antagonists.
      T M Fong, H Yu, R R Huang, M A Cascieri and C J Swain
      Molecular Pharmacology December 1996, 50 (6) 1605-1611;

  7. Yung, L Y

    1. Inverse agonistic effect of ICI-174,864 on the cloned delta-opioid receptor: role of G protein and adenylyl cyclase activation.
      T T Chiu, L Y Yung and Y H Wong
      Molecular Pharmacology December 1996, 50 (6) 1651-1657;

Z

  1. Zakut, H

    1. Overlapping drug interaction sites of human butyrylcholinesterase dissected by site-directed mutagenesis.
      Y Loewenstein-Lichtenstein, D Glick, N Gluzman, M Sternfeld, H Zakut and H Soreq
      Molecular Pharmacology December 1996, 50 (6) 1423-1431;

  2. Zalewska, T

    1. The third extracellular loop of the human delta-opioid receptor determines the selectivity of delta-opioid agonists.
      E V Varga, X Li, D Stropova, T Zalewska, R S Landsman, R J Knapp, E Malatynska, K Kawai, A Mizusura, H Nagase, S N Calderon, K Rice, V J Hruby, W R Roeske and H I Yamamura
      Molecular Pharmacology December 1996, 50 (6) 1619-1624;

  3. Zhang, J

    1. Basis for the loss of aryl hydrocarbon receptor gene expression in clones of a mouse hepatoma cell line.
      J Zhang, A J Watson, M R Probst, E Minehart and O Hankinson
      Molecular Pharmacology December 1996, 50 (6) 1454-1462;

  4. Zorumski, C F

    1. Enantioselectivity of steroid-induced gamma-aminobutyric acidA receptor modulation and anesthesia.
      L L Wittmer, Y Hu, M Kalkbrenner, A S Evers, C F Zorumski and D F Covey
      Molecular Pharmacology December 1996, 50 (6) 1581-1586;

  5. Zunino, F

    1. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIalpha (p170) and IIbeta (p180).
      M Cornarotti, S Tinelli, E Willmore, F Zunino, L M Fisher, C A Austin and G Capranico
      Molecular Pharmacology December 1996, 50 (6) 1463-1471;
Back to top

In this issue

Advertisement